Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma

Fan,Juan; Du,Jiangrong; Wu,Jingbo; Fu,Shaozhi; Hu,Defeng; Wan,Qiang

doi:10.3892/ol.2014.2783

Antitumor effects of different administration sequences of cisplatin and Endostar on Lewis lung carcinoma

Authors:
- Juan Fan
- Jiangrong Du
- Jingbo Wu
- Shaozhi Fu
- Defeng Hu
- Qiang Wan
View Affiliations

Affiliations: Department of Oncology, The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China, Department of Nuclear Medicine, Luzhou Medical College, Luzhou, Sichuan 646000, P.R. China
Published online on: December 9, 2014 https://doi.org/10.3892/ol.2014.2783
Pages: 822-828

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis plays an essential role in the growth and metastasis of a number of tumors. Anti‑angiogenic drugs are able to normalize tumor vasculature and inhibit tumor growth. Therefore, it has been hypothesized that the combination of cytotoxic chemotherapy drugs and angiogenesis inhibitors may exert complementary therapeutic benefits in the treatment of cancer. In the present study, the effect of the angiogenesis inhibitor, recombinant human endostatin (Endostar), in combination with cisplatin, was evaluated in C57/BL/6 mouse xenografts under different administration sequences. The drug combinations and sequences of administration were analyzed within the cancer xenografts for any inhibitory effects. Changes in the cell cycle distribution of the cells were monitored using flow cytometry. The effects of Endostar, particularly a reduction in the density of microvessels, were assessed using a method that employed anti‑cluster of differentiation 31 antibodies. The concentration of cisplatin in the blood and tumor tissue at various time‑points following administration was detected by high‑performance liquid chromatography. The tumor tissues that received simultaneous Endostar and cisplatin exhibited increased inhibition of tumor growth and improved cell cycle distribution compared with those that received cisplatin alone, or those in which Endostar was administered prior to cisplatin. The simultaneous administration of the drugs resulted in the lowest microvessel density in the xenografts. Under these conditions, the concentration of cisplatin was revealed to be the highest in the grafted tumor tissue. The results of the present study suggest that the co‑administration of Endostar and cisplatin may aid in the optimization of the antitumor activity of cisplatin.

View Figures

View References

1	Laskin JJ and Sandler AB: First-line treatment for advanced non-small-cell lung cancer. Oncology (Williston Park). 19:1671–1676; discussion 1678–1680. 2005.
2	Le Chevalier T, Scagliotti G, Natale R, et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 47:69–80. 2005. View Article : Google Scholar
3	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
4	Browder T, Butterfield CE, Kräling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878–1886. 2000.PubMed/NCBI
5	Bello L, Carrabba G, Giussani C, et al: Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 61:7501–7506. 2001.PubMed/NCBI
6	Ramalingam SS, Dahlberg SE, Langer CJ, et al; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 26:60–65. 2008. View Article : Google Scholar : PubMed/NCBI
7	Murata R, Nishimura Y and Hiraoka M: An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys. 37:1107–1113. 1997. View Article : Google Scholar : PubMed/NCBI
8	Ma J, Pulfer S, Li S, Chu J, Reed K and Gallo JM: Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res. 61:5491–5498. 2001.PubMed/NCBI
9	Lin MI and Sessa WC: Antiangiogenic therapy: creating a unique ‘window’ of opportunity. Cancer Cell. 6:529–531. 2004.PubMed/NCBI
10	Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
11	Weichselbaum RR: How does antiangiogenic therapy affect brain tumor response to radiation. Nat Clin Pract Oncol. 2:232–233. 2005. View Article : Google Scholar : PubMed/NCBI
12	Zhou ZT, Zhou FX, Wei Q, Zou LY, Qin BF and Peng XS: Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 68:1027–1032. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ma X, Yao Y, Yuan D, Liu H, Wang S, Zhou C and Song Y: Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One. 7:e534492012. View Article : Google Scholar
14	Lignet F, Benzekry S, Wilson S, et al: Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice. J Theor Biol. 320:86–99. 2013. View Article : Google Scholar
15	Mabuchi S, Terai Y, Morishige K, et al: Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clin Cancer Res. 14:7781–7789. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yuan J, Wu CW, Liu ZJ, Wei XY and Li K: Observation of the antitumor effect of endostar combined with docetaxel under different administration sequences. Zhonghua Zhong Liu Za Zhi. 32:580–585. 2010.(In Chinese). PubMed/NCBI
17	Peng XC, Qiu M, Wei M, et al: Different combination schedules of gemcitabine with endostar affect antitumor efficacy. Cancer Chemother Pharmacol. 69:239–246. 2012. View Article : Google Scholar
18	Ling Y, Yang Y, Lu N, et al: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wang J, Sun Y, Liu Y, et al: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi. 8:283–290. 2005.(In Chinese). PubMed/NCBI
20	Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl J Med. 324:1–8. 1991. View Article : Google Scholar
21	Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6:553–563. 2004.PubMed/NCBI
22	Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH and Griffin RJ: Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 13:3395–3402. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ohta M, Kawabata T, Yamamoto M, et al: TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today. 39:1046–1053. 2009. View Article : Google Scholar : PubMed/NCBI
24	Peng F, Xu Z, Wang J, et al: Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS One. 7:e346462012. View Article : Google Scholar : PubMed/NCBI
25	Xin G, Du J, Zhu L, Yu YH, Li Y and Liu PS: Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer. Zhonghua Yi Xue Za Zhi. 91:3367–3370. 2011.(In Chinese).
26	Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ and Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64:3731–3736. 2004. View Article : Google Scholar : PubMed/NCBI
27	Guşet G, Costi S, Lazăr E, Dema A, Cornianu M, Vernic C and Păiuşan L: Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma. Rom J Morphol Embryol. 51:677–682. 2010.
28	Bocci G, Nicoluaou KC and Kerbel RS: Prutracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62:6938–6943. 2002.PubMed/NCBI
29	Wu SM, Zhao YA, Yang L, Wang L, et al: Effects of recombinant human angiostatin on vascular endothelial cell. Chin J Aesthetic Med. 17:685–688. 2008.
30	You ZY, Zhao Y, Liu F, Zhang YD and Wang JJ: The radiosensitization effects of Endostar on human lung squamous cancer cells H-520. Cancer Cell Int. 10:172010. View Article : Google Scholar : PubMed/NCBI
31	Xu WJ, Huang C, Wang J, et al: Comparison of the effects of recombinant human endostatin and docetaxel on human umbilical vein endothelial cells in different growth states. Chin Med J (Engl). 124:2883–2889. 2011.